Stock Research for TNXP


Featured Broker: Ally Invest

Get the due diligence for another stock.


TNXP Stock Chart & Research Data

The TNXP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TNXP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


TNXP Due diligence Resources & Stock Charts

The TNXP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TNXP Detailed Price Forecast - CNN Money CNN View TNXP Detailed Summary - Google Finance
Yahoo View TNXP Detailed Summary - Yahoo! Finance Zacks View TNXP Stock Research & Analysis -

Stock Analysis

TradeIdeas View TNXP Trends & Analysis - Trade-Ideas Barrons View TNXP Major Holders - Barrons
NASDAQ View TNXP Call Transcripts - NASDAQ Seeking View TNXP Breaking News & Analysis - Seeking Alpha
Spotlight View TNXP Annual Report - OTC Report View TNXP OTC Short Report -
TradeKing View TNXP Fundamentals - TradeKing Charts View TNXP SEC Filings - Bar Chart
WSJ View Historical Prices for TNXP - The WSJ Morningstar View Performance/Total Return for TNXP - Morningstar
MarketWatch View the Analyst Estimates for TNXP - MarketWatch CNBC View the Earnings History for TNXP - CNBC
StockMarketWatch View the TNXP Earnings - StockMarketWatch MacroAxis View TNXP Buy or Sell Recommendations - MacroAxis
Bullish View the TNXP Bullish Patterns - American Bulls Short Pains View TNXP Short Pain Metrics -

Social Media Mentions

StockTwits View TNXP Stock Mentions - StockTwits PennyStocks View TNXP Stock Mentions - PennyStockTweets
Twitter View TNXP Stock Mentions - Twitter Invest Hub View TNXP Investment Forum News - Investor Hub
Yahoo View TNXP Stock Mentions - Yahoo! Message Board Seeking Alpha View TNXP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for TNXP - Insider Cow View Insider Transactions for TNXP - Insider Cow
CNBC View TNXP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TNXP - OTC Markets
Yahoo View Insider Transactions for TNXP - Yahoo! Finance NASDAQ View Institutional Holdings for TNXP - NASDAQ

Stock Charts

FinViz View TNXP Stock Insight & Charts - StockCharts View TNXP Investment Charts -
BarChart View TNXP Stock Overview & Charts - BarChart Trading View View TNXP User Generated Charts - Trading View

Latest Financial News for TNXP

Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
Posted on Friday December 07, 2018

Tonix Pharmaceuticals (NASDAQ:TNXP) says that it is holding a new public offering that has a total value of $15 billion. The company notes that it plans to use funds from this public offering to fuel a new Phase 3 study for TNX-102 SL, which is its lead product candidate. According to Tonix Pharmaceuticals, it will be selling Class A and Class B shares of its stock during the public offering.

Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Posted on Friday December 07, 2018

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today the pricing of an underwritten public offering with expected total gross proceeds of $15,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund a new Phase 3 study using a modified trial design for its lead product candidate, TNX-102 SL, and for working capital and other general corporate purposes. The securities offered by the Company consist of (i) Class A Units each consisting of one share of Common Stock and one Warrant to purchase one share of Common Stock at a price of $3.50 per Class A Unit, and (ii) Class B Units each consisting of one share of Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into 286 shares of Common Stock per share of Series A Preferred Stock, and Warrants to purchase 286 shares of Common Stock, at a combined price of $1,000 per Class B Unit.

Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target
Posted on Monday December 03, 2018

NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Tonix Pharmaceuticals Holding Corp. (TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of PTSD. New composition of matter patent was issued in November which expands the Company's intellectual property protection for Tonmya, or TNX-102 SL, in the U.S. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer's disease and fibromyalgia.

Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Posted on Thursday November 29, 2018

Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). The minutes are consistent with the preliminary guidance the Company received at the meeting and confirm FDA’s acceptance of the new Phase 3 “RECOVERY” study design. As previously communicated, the Company plans to start the RECOVERY trial for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.